Immunocore Q1: KIMMTRAK revenue $93.9M (+33% YoY); net income $5M vs loss year ago

Immunocore Holdings plc

2025-Q1 EPS reported $0.10 revenue$93,881,000

KIMMTRAK net sales $93.9M, up 33% YoY; US $56.6M, Europe $32.8M (incl $6M favorable adjustments), intl $4.5M.
Net income $5.0M vs net loss $24.4M in Q1 2024; diluted EPS $0.10 vs ($0.49).
Phase 3 TEBE-AM (cutaneous melanoma) enrollment on track to complete in 1H 2026; PRISM-MEL-301 dose selection expected 2H 2025.
HIV candidate IMC-M113V showed viral control in 3 of 15 evaluable patients at CROI; dose escalation continuing.
Cash and securities $837M at March 31, 2025, up from $820.4M at Dec 31, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.